AIM Rule 26
The following information is disclosed in accordance with rule 26 of the AIM Rules for Companies and was last updated on 27 September 2018
Description of business
Destiny Pharma plc is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Destiny Pharma’s Vision is of an expanding range of anti-microbial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due the existence or threat of antibiotic resistance.
Its proprietary, anti-microbial drug platform, the XF Drugs Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response
Further company information can be obtained here
Names and details of directors
Please click here for the names and brief biographical details for the directors together with a description of their responsibilities
Responsibilities of directors & committees
Please click here for information on the Audit Committee, Remuneration Committee and Nomination Committee together with the membership of those committees
Country of incorporation and operation
Destiny Pharma plc is incorporated in England and Wales and the UK is the Company’s main country of operation. Details of the Company’s registered office can be found here
The Company’s Articles of Association can be downloaded here
Shares in Destiny Pharma plc are not traded on any exchanges or trading platforms other than the AIM market
Please click here for details of the number of securities in issue, the number of securities held as treasury shares and, insofar as the Company is aware, the percentage of securities that is not in public hands together with the identity and percentage holdings of significant shareholders
Please click here for access to the Company’s annual and interim reports
Please click here to access the notifications made by the Company
The admission document can be downloaded here
As an AIM Company, Destiny Pharma has adopted as far as possible the principles of the Quoted Companies Alliance Corporate Governance Code (the “QCA Code”). The QCA Code identifies ten principles to be followed in order for companies to deliver growth in long term shareholder value, encompassing and efficient, effective and dynamic management framework accompanied by good communication to promote confidence and trust. Further details can be found here.
The Company is subject to the UK City Code on Takeovers and Mergers (the City Code) issued and administered by the Panel on Takeovers and Mergers (the Takeover Panel)
Please click here for information on the Company’s advisers, including contact details